These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18587585)

  • 1. [Legal regulations to produce serum eye drops : when is it necessary, and how can it be obtained?].
    Geerling G; Grus F; Seitz B; Hartwig D; Schirra F
    Ophthalmologe; 2008 Jul; 105(7):632-8. PubMed ID: 18587585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the use of autologous serum eyedrops in Germany : results of a survey among members of the Cornea Section of the German Ophthalmological Society (DOG)].
    Kasper K; Godenschweger L; Hartwig D; Unterlauft JD; Seitz B; Geerling G
    Ophthalmologe; 2008 Jul; 105(7):644-9. PubMed ID: 18612645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of standardized guidelines for the production and quality control of autologous serum eye drops in Korea: based on a nationwide survey.
    Lee HR; Hong YJ; Chung S; Hwang SM; Kim TS; Song EY; Park KU; Song J; Han KS
    Transfusion; 2014 Jul; 54(7):1864-70. PubMed ID: 24617756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autologous serum and alternative blood products for the treatment of ocular surface disorders].
    Geerling G; Unterlauft JD; Kasper K; Schrader S; Opitz A; Hartwig D
    Ophthalmologe; 2008 Jul; 105(7):623-31. PubMed ID: 18607606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Manufacture of autologous serum eye drops for out-patient therapy : cooperation between ophthalmic clinic and transfusion medicine department].
    Dietrich T; Weisbach V; Seitz B; Jacobi C; Kruse FE; Eckstein R; Cursiefen C
    Ophthalmologe; 2008 Nov; 105(11):1036-8, 1040-2. PubMed ID: 18506408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experiences with a centralised national service for autologous serum eyedrops in England].
    Maclennan S; Hartwig D; Geerling G
    Ophthalmologe; 2008 Jul; 105(7):639-43. PubMed ID: 18592251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [National and European drug approval procedures].
    Mohrbutter KP
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):593-6. PubMed ID: 9527447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of alcohol-based hand disinfectants and their regulatory status. Development and marketing authorisation.
    Stengele M
    J Hosp Infect; 2008 Oct; 70 Suppl 1():49-54. PubMed ID: 18994682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous serum for ocular surface diseases.
    Quinto GG; Campos M; Behrens A
    Arq Bras Oftalmol; 2008; 71(6 Suppl):47-54. PubMed ID: 19274411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The elaboration, use and evaluation of eye-drops with autologous serum in corneal lesions].
    García Jiménez V; Veiga Villaverde B; Baamonde Arbaiza B; Cahue Carpintero I; Celemín Viñuela ML; Simó Martínez RM
    Farm Hosp; 2003; 27(1):21-5. PubMed ID: 12607012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous serum eye drops for the treatment of dry eye diseases.
    Kojima T; Higuchi A; Goto E; Matsumoto Y; Dogru M; Tsubota K
    Cornea; 2008 Sep; 27 Suppl 1():S25-30. PubMed ID: 18813071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Albumin eye drops for treatment of ocular surface diseases].
    Unterlauft JD; Kohlhaas M; Hofbauer I; Kasper K; Geerling G
    Ophthalmologe; 2009 Oct; 106(10):932-7. PubMed ID: 19813016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 20. [Compassionate use mechanisms in Europe].
    Sugimura N
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):287-9. PubMed ID: 17301545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.